The FDA granted a new indication for Frogmen injection, for subcutaneous use, to reduce the recurrence of symptomatic VTE in pediatric patients aged 1 month and older. Source link
The low-molecular-weight heparin is indicated to reduce the recurrence of symptomatic venous thromboembolism in children as young as 1 month. FDA Approvals Source link
© 2017 Worldnews Media LLC. All Rights Reserved.